Case Reports
Cardiac Amyloidosis, Follow the Trail Not to Miss the Diagnosis
Main Article Content
Silvia Ribeiro
Filipa Cordeiro
João Costa
Abstract
Amyloidosis is a systemic disease caused by the extracellular deposition of insoluble fibrils of low molecular weight proteins, the most common of which are light chains (AL amyloidosis) and transthyretin (ATTR amyloidosis), the latter in acquired (wild type) or hereditary form. Despite being considered rare, its underdiagnosis is now recognized, meaning that a high index of suspicion is essential in order to modify the morbidity and mortality of patients affected by it.
The authors describe a case report of amyloidosis with cardiac involvement.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
References
Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C, et al. 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J. 2023;44:3503-626. doi: 10.1093/eurheartj/ehad194.
Writing Committee; Kittleson MM, Ruberg FL, Ambardekar AV, Brannagan TH, Cheng RK, Clarke JO, et al. 2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2023;81:1076-126. doi: 10.1016/j.jacc.2022.11.022. Erratum in: J Am Coll Cardiol. 2023;81:1135. doi: 10.1016/j.jacc.2023.02.013.
Gonzalez-Lopez E, Gallego-Delgado M, Guzzo-Merello G, de Haro-Del Moral FJ, Cobo-Marcos M, Robles C, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015;36:2585–94. doi:10.1093/eurheartj/ehv338.
Castano A, Narotsky DL, Hamid N, Khalique OK, Morgenstern R, DeLuca A, et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J. 2017;38:2879–87. doi.org/10.1093/eurheartj/ehx350.
Lousada I, Comenzo RL, Landau H, Guthrie S, Merlini G. Light chain amyloidosis: Patient Experience Survey from the Amyloidosis Research Consortium. Adv Ther. 2015;32:920-8. doi: 10.1007/s12325-015-0250-0.
Lane T, Fontana M, Martinez-Naharro A, Quarta CC, Whelan CJ, Petrie A, et al. Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis. Circulation. 2019;140:16-26. doi: 10.1161/CIRCULATIONAHA.118.038169.
Tanskanen M, Peuralinna T, Polvikoski T, Notkola IL, Sulkava R, Hardy J, et al. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Ann Med. 2008;40:232-9. doi: 10.1080/07853890701842988.
Cornwell GG 3rd, Murdoch WL, Kyle RA, Westermark P, Pitkänen P. Frequency and distribution of senile cardiovascular amyloid. A clinicopathologic correlation. Am J Med. 1983;75:618-23. doi: 10.1016/0002-9343(83)90443-6.
Quarta CC, Zheng J, Hutt D, Grigore SF, Manwani R, Sachchithanantham S, et al. 99mTc-DPD scintigraphy in immunoglobulin light chain (AL) cardiac amyloidosis. Eur Heart J Cardiovasc Imaging. 2021;22:1304-11. doi: 10.1093/ehjci/jeab095.
Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2021;42:1554–68. doi. org/10.1093/eurheartj/ehab072.
Maestro-Benedicto A, Vela P, de Frutos F, Mora N, Pomares A, Gonzalez-Vioque E, et al. Frequency of hereditary transthyretin amyloidosis among elderly patients with transthyretin cardiomyopathy. Eur J Heart Fail. 2022;24:2367-73. doi: 10.1002/ejhf.2658.
Glikson M, Nielsen JC, Kronborg MB, Michowitz Y, Auricchio A, Barbash IM, et al. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Eur Heart J. 2021;42:3427-520. doi: 10.1093/eurheartj/ehab364.
Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2018;379:1007-16. doi: 10.1056/NEJMoa1805689.
